NASDAQ:CANF - Can-Fite Biopharma News Headlines

$3.19
+0.09 (+2.90 %)
(As of 07/17/2019 04:00 PM ET)
Today's Range
$3.11
Now: $3.19
$3.23
50-Day Range
$2.73
MA: $2.95
$3.20
52-Week Range
$2.66
Now: $3.19
$25.95
Volume138,130 shs
Average Volume126,621 shs
Market Capitalization$4.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

Can-Fite Biopharma (NASDAQ CANF) News Headlines

Source:
DateHeadline
Zacks: Can-Fite Biopharma Ltd (NASDAQ:CANF) Given Consensus Recommendation of "Strong Buy" by AnalystsZacks: Can-Fite Biopharma Ltd (NASDAQ:CANF) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - July 13 at 8:24 AM
 Brokerages Expect Can-Fite Biopharma Ltd (NASDAQ:CANF) Will Post Earnings of -$0.80 Per Share Brokerages Expect Can-Fite Biopharma Ltd (NASDAQ:CANF) Will Post Earnings of -$0.80 Per Share
www.americanbankingnews.com - July 11 at 6:31 AM
Can-Fite BioPharma Appeals Lawsuit Against Venture Capital FirmCan-Fite BioPharma Appeals Lawsuit Against Venture Capital Firm
www.benzinga.com - July 10 at 11:24 AM
All You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong BuyAll You Need to Know About Can-Fite (CANF) Rating Upgrade to Strong Buy
finance.yahoo.com - June 20 at 11:34 AM
Can-Fite Biopharma Ltd Sponsored ADR (Israel) Real Time Stock QuotesCan-Fite Biopharma Ltd Sponsored ADR (Israel) Real Time Stock Quotes
www.nasdaq.com - June 17 at 3:47 PM
Can-Fite Abstract Selected For Liver ConferenceCan-Fite Abstract Selected For Liver Conference
finance.yahoo.com - May 20 at 3:56 PM
Can-Fite BioPharma Announces $6 Million Registered Direct OfferingCan-Fite BioPharma Announces $6 Million Registered Direct Offering
finance.yahoo.com - May 20 at 3:56 PM
Can-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South KoreaCan-Fite Receives $1,000,000 Payment from CKD for Distribution of Namodenoson in South Korea
finance.yahoo.com - April 15 at 8:53 AM
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual MeetingCan-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 10 at 8:12 AM
Can-Fite Biopharma Ltd. ADRCan-Fite Biopharma Ltd. ADR
www.barrons.com - March 26 at 12:28 PM
Four Marijuana Stocks on the Rise on WednesdayFour Marijuana Stocks on the Rise on Wednesday
finance.yahoo.com - March 20 at 3:51 PM
Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis DrugCan-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Osteoarthritis Drug
finance.yahoo.com - February 4 at 8:47 AM
Can-Fite BioPharma (CANF) Presents At Biotech Showcase Investor Conference - SlideshowCan-Fite BioPharma (CANF) Presents At Biotech Showcase Investor Conference - Slideshow
seekingalpha.com - January 10 at 3:28 PM
Can-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development UpdateCan-Fite Reports Third Quarter 2018 Financial Results and Provides Clinical Development Update
finance.yahoo.com - November 30 at 8:36 AM
Prior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist ExpertPrior to Phase II Liver Cancer Data Release Can-Fite Brings on Board an Oncologist Expert
finance.yahoo.com - November 20 at 8:19 AM
Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
finance.yahoo.com - October 31 at 7:46 AM
Can-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor ConferenceCan-Fite to Present on its Liver Cancer Drug Namodenoson at the NYC Oncology Investor Conference
finance.yahoo.com - October 25 at 7:36 AM
Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018Can-Fite CEO to present as Expert Speaker on Namodenoson at NASH Summit Europe 2018
finance.yahoo.com - October 18 at 7:39 AM
Can-Fite Biopharma net loss improves in 1HCan-Fite Biopharma net loss improves in 1H
seekingalpha.com - August 31 at 3:16 PM
Can-Fite enrolls first patient in its Comfort Phase III trial of Piclidenoson in PsoriasisCan-Fite enrolls first patient in its Comfort Phase III trial of Piclidenoson in Psoriasis
seekingalpha.com - August 21 at 3:16 PM
Can-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in ChinaCan-Fite Receives from CMS Medical Venture Investment Limited $2,000,000 Upfront Payment as Part of Development, Registration and Marketing Agreement for Piclidenoson and Namodenoson in China
finance.yahoo.com - August 7 at 3:15 PM
Can-Fite BioPharma (CANF) Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS MedicalCan-Fite BioPharma (CANF) Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
www.streetinsider.com - August 6 at 8:00 AM
BRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution AgreementBRIEF-China Medical System Holdings Says It Signed License, Collaboration & Distribution Agreement
finance.yahoo.com - August 6 at 8:00 AM
Can-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS MedicalCan-Fite Signs Multi-Million Dollar Development and Distribution Agreement for Piclidenoson and Namodenoson in China with CMS Medical
finance.yahoo.com - August 6 at 8:00 AM
Can-Fite 12 Months Activities & Milestones for 2018Can-Fite 12 Months' Activities & Milestones for 2018
finance.yahoo.com - January 11 at 8:35 AM
Can-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro Holdings - StreetInsider.comCan-Fite (CANF) Enters Distribution Agreement for Piclidenoson in Three European Countries with Gebro Holdings - StreetInsider.com
www.streetinsider.com - January 9 at 6:38 PM
Can-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro HoldingsCan-Fite Signs Multi-Million Dollar Distribution Agreement for Piclidenoson in 3 European Countries with Gebro Holdings
finance.yahoo.com - January 8 at 8:52 AM
Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Can-Fite BioPharma Ltd. :CANF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 9:55 AM
Can-Fite Reports on the Progress of Its Phase II Liver Cancer with NamodenosonCan-Fite Reports on the Progress of Its Phase II Liver Cancer with Namodenoson
finance.yahoo.com - December 18 at 8:21 AM
Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection CenterWired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center
finance.yahoo.com - December 13 at 8:22 AM
Can-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson - StreetInsider.comCan-Fite BioPharma (CANF) Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson - StreetInsider.com
www.streetinsider.com - November 29 at 8:13 AM
Can-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with NamodenosonCan-Fite Enrolls First Patient in Phase II NAFLD/NASH Study with Namodenoson
finance.yahoo.com - November 27 at 6:23 PM
Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical UpdateCan-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update
finance.yahoo.com - November 27 at 6:23 PM
Can-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger with Wize PharmaCan-Fite’s Former Subsidiary OphthaliX Successfully Completes Merger with Wize Pharma
finance.yahoo.com - November 17 at 2:33 PM
Earnings Review and Free Research Report: Can-Fite’s Revenue Increased 25%Earnings Review and Free Research Report: Can-Fite’s Revenue Increased 25%
finance.yahoo.com - September 25 at 7:53 PM
Can-Fite BioPharma (CANF) Receives Notice of Allowance in Europe for Piclidenoson-Related PatentCan-Fite BioPharma (CANF) Receives Notice of Allowance in Europe for Piclidenoson-Related Patent
www.streetinsider.com - September 13 at 8:54 AM
Can-Fite Biopharma revenues up 33% in 1H16Can-Fite Biopharma revenues up 33% in 1H16
seekingalpha.com - August 26 at 12:06 PM
Can-Fite BioPharma (CANF) Posts Wider Net Loss in H116Can-Fite BioPharma (CANF) Posts Wider Net Loss in H116
www.streetinsider.com - August 26 at 12:06 PM
Can-Fite Catapults NASH Indication Into Phase II Aiming for $35 Billion MarketCan-Fite Catapults NASH Indication Into Phase II Aiming for $35 Billion Market
www.baystreet.ca - July 28 at 12:49 PM
Mid-Morning Market Update: Markets Open Lower; Teslas Deliveries Hit Near 2-Year LowMid-Morning Market Update: Markets Open Lower; Tesla's Deliveries Hit Near 2-Year Low
www.benzinga.com - July 5 at 4:01 PM
Can-Fite Bios lead product candidate flunks mid-stage glaucoma study; shares down 23% premarketCan-Fite Bio's lead product candidate flunks mid-stage glaucoma study; shares down 23% premarket
seekingalpha.com - July 5 at 4:01 PM
Can-Fite BioPharma (CANF) Announces New Data Showing CF101 May Offer Efficacy Similar to Leading Biologics Without Harmful Side EffectsCan-Fite BioPharma (CANF) Announces New Data Showing CF101 May Offer Efficacy Similar to Leading Biologics Without Harmful Side Effects
www.streetinsider.com - June 15 at 4:08 PM
Can-Fite finalizes design of late-stage study of CF101 in rheumatoid arthritis, enrollment to start no later than Q3Can-Fite finalizes design of late-stage study of CF101 in rheumatoid arthritis, enrollment to start no later than Q3
seekingalpha.com - June 3 at 8:20 AM
Can-Fite BioPharma (CANF) Will Present CF602 Data at AUA 2016 - StreetInsider.comCan-Fite BioPharma (CANF) Will Present CF602 Data at AUA 2016 - StreetInsider.com
www.streetinsider.com - May 2 at 9:17 AM
Can-Fite BioPharma (CANF) Announces Positive New Pre-Clinical Data for CF602 - StreetInsider.comCan-Fite BioPharma (CANF) Announces Positive New Pre-Clinical Data for CF602 - StreetInsider.com
www.streetinsider.com - April 12 at 1:03 PM
Form 6-K Can-Fite BioPharma Ltd. For: Apr 01 - StreetInsider.comForm 6-K Can-Fite BioPharma Ltd. For: Apr 01 - StreetInsider.com
www.streetinsider.com - April 1 at 3:00 PM
Can-Fite BioPharma (CANF) Submits EMA Protocol Design for Phase III Trial of Lead Compound CF101 - StreetInsider.comCan-Fite BioPharma (CANF) Submits EMA Protocol Design for Phase III Trial of Lead Compound CF101 - StreetInsider.com
www.streetinsider.com - March 18 at 2:19 PM
Transcript of the Republican Presidential Debate in Florida - New York TimesTranscript of the Republican Presidential Debate in Florida - New York Times
www.nytimes.com - March 12 at 1:41 PM
Transcript of Republican debate in Miami, full text - CNN InternationalTranscript of Republican debate in Miami, full text - CNN International
www.cnn.com - March 12 at 1:41 PM
Hottest Manufacturing Stocks Now - CRMD TUMI JOY TSE - Investorplace.comHottest Manufacturing Stocks Now - CRMD TUMI JOY TSE - Investorplace.com
investorplace.com - March 3 at 2:53 PM
This page was last updated on 7/17/2019 by MarketBeat.com Staff

Featured Article: Accumulation/Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel